TICKERNERD
Menu
RVMDRVMDHealthcare · Biotechnology

RVMD Stock Forecast: Revolution Medicines, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$188
−6.35% on the day

The 24 Wall Street analysts covering Revolution Medicines, Inc. hold a median 12-month price target of $260 — +38.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$42.8B
Ticker Nerd rank
45 / 100
Median analyst target
$260
Analysts covering
24
Revenue$0.0
Operating income−$505.1M
Net income−$644.4M
Free cash flow−$745.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.6%
1M
−9.3%
YTD
+136.2%
1Y
+293.4%
From 52W high
−14.9%
From 52W low
+296.0%
$48
$221
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RVMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Revolution Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Value
90
Volatility
67
Accruals
58
Revisions
55
Quality
47
Growth
27
Issuance
9
Size
6

Momentum (99): The shares have been drifting up relative to others.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RVMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RVMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200$250$300$350Jan 26Apr 26Jul 26Oct 26RVMDHigh $320Median $260Low $179

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
23 Buy1 Hold0 Sell
Low $179Median $260High $320

The green dot is the last close — the median target sits +38.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 Sept 2026Brookline CapitalInitiatesBuy$318
24 Sept 2026Goldman SachsReinstatesBuy$267
21 Sept 2026B of A SecuritiesMaintainsBuy$225 → $265
10 Sept 2026Morgan StanleyInitiatesOverweight$255
10 Sept 2026Morgan StanleyInitiatesOverweight—
9 Sept 2026StifelMaintainsBuy$215 → $230
9 Sept 2026StifelMaintainsBuy—
31 Aug 2026NeedhamMaintainsBuy—
31 Aug 2026NeedhamMaintainsBuy$240 → $275
28 Aug 2026GuggenheimMaintainsBuy$240 → $275
28 Aug 2026GuggenheimMaintainsBuy—
28 Aug 2026UBSMaintainsBuy$220 → $265
28 Aug 2026UBSMaintainsBuy—
27 Aug 2026Evercore ISI GroupMaintainsOutperform$230 → $320
27 Aug 2026Evercore ISI GroupMaintainsOutperform—
27 Aug 2026HC Wainwright & Co.MaintainsBuy$195 → $280
27 Aug 2026HC Wainwright & Co.MaintainsBuy—
27 Aug 2026OppenheimerMaintainsOutperform$230 → $260
27 Aug 2026OppenheimerMaintainsOutperform—
27 Aug 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RVMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RVMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Revolution Medicines, Inc. returned +293.4% against +16.2% for the S&P 500, dividends included.

RVMD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26RVMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RVMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
10
Analysts cutting
5
Fundamentals

Revolution Medicines, Inc. (RVMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−33.2×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
16.4×

Cheaper than 6% of US stocks

EV / EBITDA
−24.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−79.1%

Higher than 16% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Revolution Medicines, Inc. (RVMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Revolution Medicines, Inc. has a market value of $42.8B and an enterprise value of $40.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$1.8B.

  • Diluted earnings per share, trailing twelve months: $−8.82.

  • Free cash flow in the twelve months to 30 June 2026: −$1.6B.

  • Shares outstanding: 214.2M.

  • Trailing P/E: −33.2×; forward P/E: −35.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Revolution Medicines, Inc. employs 883 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

RVMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RVMDRevolution Medicines, Inc.$42.8B
45
RPRXRoyalty Pharma plc$32.4B
87
ALNYAlnylam Pharmaceuticals, Inc.$29.7B
51
ROIVRoivant Sciences Ltd.$24.5B
35
INCYIncyte Corp.$22.5B
89
INSMInsmed, Inc.$21.9B
81
REGNRegeneron Pharmaceuticals, Inc.$77.7B
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Revolution Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RVMD news & analysis

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

GlobeNewsWire · 5 Oct 2026positive

Revolution Medicines announced it has begun treating patients in RASolute 309, a global, randomized Phase 3 trial evaluating the combination of RASONQUE (daraxonrasib) and zoldonrasib as a first-line treatment for adults with metastatic RAS G12D pancreatic adenocarcinoma. The trial is designed to assess the two investigational RAS(ON) inhibitors in this patient population.

Why it matters — This marks the initiation of a pivotal Phase 3 trial for a key combination therapy in a difficult-to-treat pancreatic cancer setting, representing a significant clinical development milestone for Revolution Medicines' pipeline.

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

The Motley Fool · 25 Sept 2026positive

Revolution Medicines has received positive news regarding a drug intended to treat pancreatic cancer, as reported by The Motley Fool. The article notes that while the company has multiple drugs in development, investing directly in Revolution Medicines remains a concentrated bet relative to alternatives like Royalty Pharma.

Why it matters — RVMD watchers would care because the announcement is favorable news for the company's pancreatic cancer drug program, though it also highlights the concentrated risk profile of a direct investment in the company.

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 18 Sept 2026neutral

Revolution Medicines is highlighted in a Motley Fool comparison article that examines it against Axsome Therapeutics as a potential investment for 2026. The article notes that Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors to treat difficult cancers, while Axsome focuses on commercialized central nervous system treatments.

Why it matters — The article provides a comparative overview that underscores Revolution Medicines' oncology pipeline, which is relevant context for investors tracking the company's development-stage prospects.

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?

The Motley Fool · 17 Sept 2026positive

Revolution Medicines received a recent regulatory approval for its new cancer treatment, validating its approach. The company notes the medicine might become the top-prescribed treatment in its indication.

Why it matters — A regulatory approval validates Revolution Medicines' approach and positions its new medicine to potentially become the top-prescribed treatment in its indication.

Baron Health Care Fund Q2 2026 Portfolio Activity

Seeking Alpha · 16 Sept 2026neutral

The Baron Health Care Fund reported its Q2 2026 portfolio activity, noting it added eight new positions and exited six, bringing total holdings to 43. New positions included Sartorius Stedim Biotech, a supplier of equipment and reagents to biopharmaceutical companies, and re-established positions in UnitedHealth Group and Elevance Health.

Why it matters — Revolution Medicines watchers would care because the report describes broad sector investment trends among biopharmaceutical suppliers and health care companies, offering context on how the fund views the health care space.

FAQ

Frequently asked questions about RVMD stock

What is the RVMD stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Revolution Medicines, Inc. have a median 12-month price target of $260, with estimates ranging from $179 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RVMD stock a buy right now?

Of the 24 analysts covering Revolution Medicines, Inc., 23 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revolution Medicines, Inc. 45 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RVMD?

As at 8 Oct 2026, Revolution Medicines, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will RVMD stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +38.2% from the last close, and Ticker Nerd's factor model ranks Revolution Medicines, Inc. 45 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RVMD stock forecast for 2030?

No analyst covering Revolution Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $179 to $320 over the next 12 months.

How has RVMD stock performed over the past year?

Revolution Medicines, Inc. returned +293.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Revolution Medicines, Inc. do?

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers.

What is the latest news on RVMD?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer". Revolution Medicines announced it has begun treating patients in RASolute 309, a global, randomized Phase 3 trial evaluating the combination of RASONQUE (daraxonrasib) and zoldonrasib as a first-line treatment for adults with metastatic RAS G12D pancreatic adenocarcinoma. The trial is designed to assess the two investigational RAS(ON) inhibitors in this patient population.

Company

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.

CEO Dr. Mark A. Goldsmith M.D., Ph.D. · 883 employees · United States · https://www.revmed.com